Immuno-Oncology

miCAR: combining microRNA gene silencing with CAR expression 4:17
miCAR: combining microRNA gene silencing with CAR expression
Marco Alessandrini • 20 May 2021
Developing CAR T-cell therapy for HIV 4:37
Developing CAR T-cell therapy for HIV
Marco Alessandrini • 20 May 2021
Hypoimmunogenic iPSCs: avoiding immune rejection 5:05
Hypoimmunogenic iPSCs: avoiding immune rejection
Sonja Schrepfer • 27 May 2021
DARIC33 CAR T-cells in AML 2:38
DARIC33 CAR T-cells in AML
Jacob Appelbaum • 12 May 2021
Advances in cell-based therapies for MS 4:55
Advances in cell-based therapies for MS
Jakob Dupont • 17 Jun 2021
ATA188: an allogeneic EBV-specific T cell therapy for progressive MS 5:20
ATA188: an allogeneic EBV-specific T cell therapy for progressive MS
Jakob Dupont • 17 Jun 2021
Characterization of ATA188: an off-the-shelf therapy for MS 4:08
Characterization of ATA188: an off-the-shelf therapy for MS
Jakob Dupont • 17 Jun 2021
Advances in CAR T-cell expansion technology 11:41
Advances in CAR T-cell expansion technology
Lei Yu • 3 Jun 2021
Challenges of CAR T-cell therapy for AML: is CD38 the answer? 6:10
Challenges of CAR T-cell therapy for AML: is CD38 the answer?
Lei Yu • 3 Jun 2021
Targeting solid tumors: SPEAR T-cells & HLA-independent TCRs 3:06
Targeting solid tumors: SPEAR T-cells & HLA-independent TCRs
Jo Brewer • 7 Apr 2021
SPEARHEAD-1: ADP-A2M4 in synovial sarcoma and MRCLS 1:09
SPEARHEAD-1: ADP-A2M4 in synovial sarcoma and MRCLS
Jo Brewer • 7 Apr 2021
SURPASS: evaluating the next-generation of SPEAR T-cell therapy 1:22
SURPASS: evaluating the next-generation of SPEAR T-cell therapy
Jo Brewer • 7 Apr 2021
Off-the-shelf iPSC therapies for solid tumors 4:23
Off-the-shelf iPSC therapies for solid tumors
Jo Brewer • 7 Apr 2021
Innovations within the CAR T-cell field 1:40
Innovations within the CAR T-cell field
Hong Ma • 19 Feb 2021
Allogenic NKX101 in r/r AML 2:56
Allogenic NKX101 in r/r AML
James Trager • 22 Feb 2021
Horizon scanning in anti-CD19 CAR T-cell therapy 3:07
Horizon scanning in anti-CD19 CAR T-cell therapy
Marco Alessandrini • 20 May 2021
The content of VJRegenMed is intended for healthcare professionals